Domainex prepares for expansion

Appoints Barry Knight as Chief Financial Officer and Company Secretary, and Thomas Mander as Chief Operating Officer

UK-based drug discovery services company Domainex has appointed Barry Knight as Chief Financial Officer and Company Secretary.

Knight is a Chartered Accountant and brings extensive financial expertise to Domainex, having been an executive director for life sciences companies for more than 25 years. He was previously Finance Director of both Trigen Holdings and Fulcrum Pharma. Most recently, he was COO at Kinapse.

Tom Mander started his career as a Senior Scientist with Xenova before becoming a group leader managing high-throughput screening at Glaxo Wellcome. He has been involved in the contract drug discovery and translational research sector for the past 16 years. He held operational, business development, and marketing roles at Evotec before taking executive management positions at Tripos Discovery Research (Vice President of Business Development) and Asterand (Vice President of Sales and Marketing).

Mander joins Domainex from the Early Discovery division of Charles River, formerly BioFocus, where he was Director of Business Development. He will take responsibility for leading the Domainex service division.

You may also like

Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Design & Build

New biology centre opened by HM Lord-Lieutenant of Cambridgeshire

The new three-storey facility provides over 24,000 sqft for Domainex’s expanding biology/bioanalytical departments
Research & Development

Domainex opens dedicated facility at Unity Campus

“The investment into our new facility has allowed us to create a fully dedicated suite of labs to conduct our biology services”
Drug Delivery

Parkinson’s UK and Domainex collaborate on inflammation therapy

The organisations plan to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s
Research & Development

Queen’s University Belfast enters FLIP inhibitor collaboration

The university will work with Ipsen on the inhibitors, which have been supported by Domainex
Research & Development

Expanding the medicinal chemist’s toolbox

Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Research & Development

Apeiron and Domainex partner to progress drug discovery

The companies have previously collaborated on hit identification, both fragment-based and virtual screening
Subscribe now